B. Visseaux, F. Damond, S. Matheron, D. Descamps, and C. Charpentier, Hiv-2 molecular epidemiology, Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis, 2016.

N. R. Faria, I. Hodges-mameletzis, J. C. Silva, E. S. Rodé-s-b, and S. Paolucci, Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A, J Gen Virol, vol.93, pp.889-99, 2012.

O. T. Campbell-yesufu and R. T. Gandhi, Update on human immunodeficiency virus (HIV)-2 infection, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.52, issue.6, pp.780-787, 2011.

J. Ren, L. E. Bird, P. P. Chamberlain, G. B. Stewart-jones, D. I. Stuart et al., Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors, Proc Natl Acad Sci, vol.99, issue.22, pp.14410-14415, 2002.

M. Witvrouw, C. Pannecouque, W. M. Switzer, T. M. Folks, D. Clercq et al., Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis, Antivir Ther, vol.9, issue.1, pp.57-65, 2004.

A. Benard, A. Van-sighem, A. Taieb, E. Valadas, J. Ruelle et al., Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatmentnaive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.52, issue.10, pp.1257-66, 2011.

G. S. Gottlieb, S. Eholié, J. N. Nkengasong, S. Jallow, R. et al., A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa: AIDS, vol.22, pp.2069-72, 2008.

S. Matheron, HIV-2 infection: a call for controlled trials: AIDS, vol.22, pp.2073-2077, 2008.

. Who and . Who-|, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013.

P. Morlat, Prise en charge mé dicale des personnes vivant avec le VIH Infection VIH-2

, France: Conseil national du Sida, Diversité des VIH-1, p.18, 2016.

, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, Panel on Antiretroviral Guidelines for Adults and Adolescents, p.288, 2017.

Y. Gilleece, D. R. Chadwick, J. Breuer, D. Hawkins, E. Smit et al., British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010, HIV Med, vol.11, issue.10, p.20961377, 2010.

, Update of recommendations on first-and second-line antiretroviral regimens, p.16, 2019.

. Pnls-cô-te-d'ivoire, Directives nationales 2015 de Prise En Charge des Personnes Vivant avec le VIH, 2015.

C. Charpentier, S. Eholié, X. Anglaret, M. Bertine, C. Rouzioux et al., Genotypic resistance profiles of HIV-2-treated patients in West Africa, AIDS Lond Engl, vol.28, issue.8, pp.1161-1170, 2014.

G. S. Gottlieb, N. Badiane, S. E. Hawes, L. Fortes, M. Toure et al., Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.48, issue.4, pp.476-83, 2009.

D. N. Raugi, R. A. Smith, S. Ba, M. Toure, F. Traore et al., Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy, Antimicrob Agents Chemother, vol.57, issue.6, pp.2751-60, 2013.

S. Jallow, A. Alabi, R. Sarge-njie, K. Peterson, H. Whittle et al., Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants, J Clin Microbiol, vol.47, issue.7, pp.2200-2208, 2009.

U. Caixas, J. Ferreira, A. T. Marinho, I. Faustino, N. M. Grilo et al., Long-term maraviroc use as salvage therapy in HIV-2 infection, J Antimicrob Chemother, vol.67, issue.10, pp.2538-2547, 2012.

S. Matheron, D. Descamps, S. Gallien, A. Besseghir, P. Sellier et al., First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2), Clin Infect Dis Off Publ Infect Dis Soc Am, vol.67, issue.8, pp.1161-1168, 201828.

S. Ba, D. N. Raugi, R. A. Smith, F. Sall, F. K. Hawes et al., A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.67, issue.10, pp.1588-94, 201830.

U. Early, . Diagnosis, and . Hiv, Antiretroviral Treatment). Report No, p.82, 2018.